Introduction
Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri, is a condition in which intracranial pressure (ICP) is elevated without apparent cause. There is a predilection for obese women of childbearing age. Although the annual incidence of IIH is low (0.9/100 000), the incidence in women between 20 and 44 years of age and above 20% over ideal body weight is nearly 20 times higher than the general population [1] . Certain patient populations may differ in terms of visual prognosis and associated conditions. For example, a recent study [2 ] demonstrated that African-American patients with IIH were likely to have more aggressive disease and severe visual loss at least in one eye. Similarly, prepubertal patients with IIH may have a greater chance of an associated secondary disorder, and a worse visual prognosis than adults [3 ] . IIH is uncommon in the nonobese, men, elderly, and very young children, and alternate causes should be pursued in such cases. As the cause of IIH is unknown, diagnosis is made by excluding known causes of elevated ICP, and fulfilling the revised modified Dandy Criteria [4] :
(1) Symptoms, if present, reflect only increased ICP. (2) Signs, if present, reflect only increased ICP. No evidence exists of ventriculomegaly, mass, structural or vascular lesion on MRI or contrast-enhanced computed tomography (CT) for typical patients, MRI and magnetic resonance venography (MRV) for others.
Although imaging is by definition normal, MRI may demonstrate the so-called 'empty sella' (related perhaps to herniation of normal pituitary tissue through the diaphragma sella, Fig. 1a ) [5] , dilation of the subarachnoid space (SAS) around optic nerve, and posterior scleral flattening at the lamina cribrosa [6, 7] (Fig. 1b) . It is critical that lumbar puncture is performed in lateral decubitus position, with the patient relaxed and legs extended. Improper positioning, excessive spinal flexion, and patient agitation are potential sources of falsely elevated opening pressure [8] .
Clinical features of idiopathic intracranial hypertension
considerably being classically worse upon awakening, throbbing, and associated with photophobia or phonophobia. The IIH headache is often similar to migraine, and many patients with IIH have coexisting primary headache syndromes (migraine, tension-type headache, etc.). Also, the incidence of medication-overuse headache and analgesic rebound in such patients is high. Therefore, a detailed headache history is critical when deciding upon treatment based solely upon headache control [10 ,11] .
Asymptomatic presentations are not uncommon [12] . Some patients may have incidentally noticed papilledema during routine ophthalmic examination, which is a potential confounder in assessment of IIH incidence.
Transient visual obscurations (TVOs) are noticed in approximately 75% of IIH patients [13] . These are brief (<1 min) episodes of monocular or binocular visual loss (partial or complete), often associated with postural change. The mechanism is unclear, but may represent transient optic nerve head ischemia.
Pulsatile tinnitus occurs in up to 60% of IIH patients [13] . This relatively more specific symptom of elevated ICP is not generally mentioned unless the patient is specifically questioned.
Papilledema (optic disc swelling secondary to elevated ICP) is the ophthalmologic hallmark of IIH (Fig. 2) . It should be distinguished from pseudopapilledema due to optic disc drusen and congenital optic disc anomalies. There are no features of the disc appearance itself to distinguish papilledema from other causes of disc edema. Signs suggesting papilledema vs. an optic neuropathy include bilaterality (usually); preservation of central vision; and presence of associated symptoms, that is, headache, pulsatile tinnitus, and TVOs. Papilledema in rare cases may be asymmetric and very rarely even absent (the latter entity is controversial and poorly defined). Compartmentalization of the SAS of the optic nerves, impeding bidirectional CSF flow from the brain, may explain this [14 ,15] .
Papilledema may result in visual loss if left untreated. The pattern and evolution of visual loss occurs predictably, and is similar to glaucoma. The progression of visual loss is independent of the cause of papilledema. For reasons that are as yet unclear, the papillomacular bundle (portion of the ganglion-cell layer subserving central vision) is spared until the very late stage of papilledema, being affected only after the rest of the visual field is lost [16] . Adequate assessment of the visual field, best accomplished through formal perimetry (automated or Goldmann), is essential in managing such patients. Enlargement of the physiologic blind spot is the earliest and in many cases the only field defect in papilledema. This simply reflects a refractive scotoma from elevation of the peripapillary retina, and in itself is not concerning. The most common pathologic-field defect is a nasal step (Fig. 3a) , or arcuate scotoma (Fig. 3b) . With time, the arcuate defects can progress, resulting in severe visual field constriction [16, 17 ] . Ultimately, central vision starts degrading; at this stage chances of recovery are poor. It should be noted that many IIH patients with papilledema may retain completely normal visual fields and function for long periods of time, despite substantial papilledema. Therefore, quantitative visual field assessment in IIH patients is critical when deciding upon treatment. Although the most common cause of central vision loss is prolonged papilledema, there are uncommon but notable situations in which early central vision loss may occur. Superimposed ischemic optic neuropathy may develop in severely swollen optic nerves, particularly in patients with associated hypertension and rapid lowering of blood pressure [17 ] . These patients present with acute vision loss and asymmetric visual acuity and fundus findings. Perhaps more commonly, severe papilledema may cause macular exudates and edema [17 ] (Fig. 4a) . In these patients, the central vision loss is due to macular edema and not papilledema, and visual prognosis is generally favorable. Moderate-to-severe papilledema may cause retinal or choroidal folds ( have good prognosis as well [18] . In all such conditions, it should be recognized that the papilledema itself is not responsible for visual loss, and there is no indication for aggressive surgical treatment [19] .
Monitoring
The most important metrics when following IIH patients are formal perimetry and fundus examination, often augmented by stereo optic disc photographs. Visual acuity is a poor marker for progression, as the papillomacular bundle is spared until advanced stages of papilledema. Recently, the role of optic nerve imaging modalities such as optical coherence tomography (OCT) has been explored as an adjunct for monitoring IIH [20] . Though this may limit the interobserver variability and provide a quantitative rather than qualitative assessment of papilledema [21 ,22 ], it has not yet been validated as an outcome marker for papilledema in IIH. A recent study [23 ] , which looked at patients who had been followed over a period of 10 years, suggests that IIH is a chronic condition, which can worsen after a period of stability, warranting long-term follow-up.
Pathogenesis
The term 'idiopathic' indicates only that the precise cause remains elusive, not that there is no specific cause. Indeed, what we term IIH may represent the final common pathway of a variety of different factors. Any unifying theory of pathogenesis for IIH must account for the following:
(1) predilection for obese women of childbearing age, (2) absence of ventriculomegaly, (3) association with systemic diseases such as cor pulmonale and polycystic ovary disease, (4) association with certain systemic medications (e.g. tetracycline) [24] .
As the cranial vault volume limit is fixed, elevated ICP can result from CSF overproduction or underabsorption. The majority of CSF is produced by the choroid plexus within the ventricular system. Although some have implicated overproduction of CSF as a unifying mechanism of IIH, there is evidence indicating that no significant difference in the production rate exists between IIH patients and controls [25] . Also, choroid plexus papilloma, the prototypical cause of CSF overproduction, invariably results in hydrocephalus, which by definition is absent in IIH [26] .
The majority of CSF is absorbed through the arachnoid villi, mostly in the brain, although spinal arachnoid granulations play some role [27 ] . Decreased absorption has been demonstrated by radioisotope cisternography [28] , favoring this theory, although precise knowledge about CSF regulation at the level of arachnoid villi is limited. These findings might help account for cases of apparent IIH related to spinal cord lesions [29, 30] .
Intracranial venous hypertension
Intracranial venous hypertension has been proposed as a unifying mechanism for IIH. The concept that increased dural venous sinus pressure was the source of increased ICP in IIH was advanced in the 1990s with direct venous manometry studies in IIH patients and studies in IIH patients undergoing bariatric surgery [31] . Morbid obesity causes increased intra-abdominal pressure and increased venous pressure, and it was postulated that diaphragmatic elevation led to increased pleural pressure that resulted in decreased venous return from the brain to the heart, raising the ICP [32] . This theory is not completely supported by physiology. It does not account for effect of gravity in the upright position or distensibility of the abdominal skin and soft-tissue. This theory would also predict a virtual IIH epidemic in the USA, and cannot explain paucity of IIH in morbidly obese men.
Vitamin A Vitamin A toxicity has long been acknowledged as a cause of severe headaches and papilledema associated with intracranial hypertension. The finding of increased levels of unbound retinol in the CSF of IIH patients suggests the involvement of vitamin A in its pathogenesis [33] . Warner et al. [34 ] demonstrated lower levels of retinolbinding protein (RBP) and higher retinol to RBP ratio in the CSF of IIH patients compared with controls after controlling for BMI, suggesting that unbound toxic retinol might interfere with pressure regulation. Another well controlled clinical study [35 ] , which examined the CSF and serum of patients matched for BMI with and without IIH demonstrated significant elevations in CSF retinoic acid in IIH patients. The mechanisms by which vitamin A and its synthetic derivatives lead to reversible ICP elevation are unknown. Vitamin A could lead to intracranial hypertension via enhanced transcription of genes involved in CSF secretion or absorption [35 ] . It has also been suggested that altered aquaporin expression is a common pathway in the pathogenesis of IIH and intracranial hypertension secondary to medications and systemic disease [36, 37] . An alternative but intriguing explanation for the association of IIH with abnormal vitamin A transport and metabolism centers on the recent recognition that RBP may act as a signaling molecule altering CSF secretion or absorption [38 ] .
Venous sinus stenosis
There has been renewed interest in the role of cerebral venous sinuses in IIH. Karahalios et al. [31] demonstrated that elevated superior sagittal sinus pressure was present in a group of IIH patients, and proposed elevated central venous pressure as a unifying mechanism of elevated ICP in IIH.
It has been suggested that IIH may be the result of venous sinus stenosis. Venography often shows narrowing of the cerebral venous sinuses leading to functional outflow obstruction in many cases of IIH, in the absence of thrombotic occlusion [39] . In one prospective blinded study [40] using MRV, substantial bilateral sinovenous stenoses were seen in 27 of 29 cases leading the authors to conclude that dural venous sinuses are anatomically different in IIH. Both external compression and partial luminal obstruction by enlarged arachnoid granulations were seen. Bono et al. [41] showed persistence of transverse sinus stenoses in IIH after normalization of CSF pressure.
Conversely, venous sinus stenosis may be a consequence rather than a cause of raised ICP. Depending on the compliance of venous sinuses, the CSF pressure elevation may compress them and exacerbate outflow obstruction, further increasing venous pressure that could extend to the feeding veins [42] . King et al. [43] showed a drop in transverse sinus pressures after direct CSF removal by cervical puncture, and there have also been reports of lateral sinus stenotic lesions resolving after CSF diversion procedures [44] , suggesting that venous hypertension is due to transverse sinus compression by raised ICP and not due to a primary obstructive process. This chain of events could also explain the apparent reduction of brain parenchymal compliance in IIH [42, 45] . Stevens et al. [46 ] used a validated mathematical model, and demonstrated that the primary cause of IIH may be a compressible, transverse sinus with the observed stenosis being a necessary characteristic of the elevated pressure.
It remains unclear whether dural venous sinus stenosis is a cause or consequence of IIH and future research may help clarify this issue better.
Metabolic and neuroendocrine
It is highly likely that metabolic and endocrine consequences of obesity, an almost ubiquitous feature of IIH patients, underlie its pathogenesis [47 ] . Adipose tissue has been identified as an active endocrine organ, with attention being drawn to its products, leptin and gherlin, as having a possible role in IIH. Fasting plasma ghrelin levels have been found to negatively correlate with BMI and leptin has been shown to positively correlate with BMI [48] [49] [50] . The dysregulation of insulin, glucose metabolism, sex hormones, adipokines (leptin and ghrelin), glucocorticoids, lipids, and free fatty acids in obesity could predispose to IIH, though presently there is inadequate evidence for specific causative pathways [47 ] .
There has been increased attention paid to sleep disorders in IIH. Sleep apnea is a well documented association, particularly in men, suggesting that in such patients, alveolar hypoventilation and nocturnal hypoxia may play a role in raised ICP [51, 52] .
Management
Once IIH has been securely diagnosed, the indications for treatment are visual field loss and symptoms of elevated ICP. Any presumed inciting factors (like tetracycline) should be eliminated. Asymptomatic patients with no visual field loss can be reasonably managed with close observation, a low-salt diet, and encouragement to lose weight. There have been no randomized clinical trials for IIH treatment and most reports are anecdotal or restricted to relatively small case series [53] . As visual loss is a serious complication of IIH, close coordination between an ophthalmologist (visual fields, fundus examination and photographs) and neurologist (headache management), or the involvement of a neuroophthalmologist is required so that therapy can be appropriately directed to halt or prevent visual loss. This can be done medically (ICP-lowering agents) or surgically. If the patient continues to have persistent headache despite normalization of visual fields and reversal of papilledema, a careful headache history is essential to exclude alternate causes (such as medication overuse), and symptomatic headache therapy should be initiated.
Weight loss
A recent study [54 ] shows that increasing BMI and percentage weight gain are associated with progressively greater risk of IIH. Even relatively small amounts of weight gain, in the 5-15% range, increased the risk of IIH compared with less than 5% weight gain. Others have also documented successful outcomes associated with weight loss and it appears that only modest weight loss (5-10% of total body weight) is needed for reversal of symptoms and signs [55] .
Intracranial pressure-lowering agents
The carbonic anhydrase inhibitor acetazolamide is the drug most commonly used to treat IIH. It reduces CSF production at the level of the choroid plexus. It is usually started at a dose of 0.5-1 g/day and can be gradually increased until clinical improvement is seen or a dose of 3-4 g/day is reached, unless the patient develops intolerable side effects. Teratogenic effects have been reported in animals, but there are no adequate human studies of its use in pregnancy. One review found no reliable reports of adverse pregnancy outcomes in women treated with acetazolamide [56] . Topiramate is an attractive treatment option for IIH as it is a partial carbonic anhydrase inhibitor, effective for primary headaches such as migraine, and has weight loss as a prominent side effect. A recent study [57 ] demonstrated its efficacy as comparable to acetazolamide to treat IIH. Furosemide has also been used to treat IIH, but is generally considered second-line treatment.
Panagopoulos et al. [58 ] treated 26 IIH patients with octreotide (somatostatin analogue) based on the hypotheses that IIH and growth hormone production are related, and had encouraging results. Further studies are needed to confirm its efficacy [58 ,59] .
Headache
Additional medication such as tricyclic antidepressants (in very low doses to prevent the side effect of weight gain) may be used to treat the headache in IIH. Nonsteroidal anti-inflammatory agents carry the risk of development of rebound headache and their use should be limited to a few days per week. Topiramate is also effective in resolving headache, with potential secondary advantages mentioned previously [60] .
Surgical management
Surgical procedures for treating refractory IIH are divided into two types: CSF and non-CSF diversion techniques. CSF diversion techniques comprise lumboperitoneal and ventriculoperitoneal shunting. Non-CSF diversion techniques include optic nerve sheath decompression (ONSF), induced weight loss by bariatric surgery, and more recently, venous sinus stenting.
Cerebrospinal fluid shunting procedures
Both ventriculoperitoneal and lumboperitoneal shunts have been employed as CSF diversion procedures, usually in cases of failed medical therapy and the setting of medically intractable headache. Their use is increasing [61] . Though CSF shunting is usually an effective symptomatic therapy and prevents visual deterioration in medically refractory IIH [62, 63] , mechanical shunt dysfunctions, infections, the need for repeated revisions, and high overall failure rate limit widespread use in IIH. The stereotactic ventriculoperitoneal shunting (SVPS) technique was recently introduced for treating patients with intracranial hypertensive disorders within a small ventricular system such as IIH due to the high rate of revisions recorded with the lumboperitoneal shunts [64, 65] . Study has shown SVPS to be relatively minimally invasive with excellent long-term results in treating refractory IIH [66 ] .
Optic nerve sheath decompression ONSF consists of creating a fenestration in the dural sheath just behind the globe. The exact mechanism of action is uncertain and may be due to CSF egress forming a chronic fistula (causing local SAS decompression and occasionally improvement also in the fellow eye) or scarring of meninges preventing transmission of high CSF pressure to the optic-nerve head. A study [67 ] looking at early postoperative MRI findings after ONSF revealed fluid collection adjacent to the decompression site supporting the idea that ONSF functions through CSF filtration.
Many large case series attest to the efficacy of this technique in stabilizing visual field and acuity especially in the short-to-medium term [68, 69] . Occasional failure of the fellow eye to improve and the asymmetry of papilledema may be explained by CSF flow resistance produced by the trabeculations of the SAS.
Bariatric surgery
Gastric exclusion procedures have been shown to produce a durable remission of IIH [70, 71] . A potential advantage of this procedure is its usefulness in treating comorbid conditions in obesity such as arterial hypertension, diabetes mellitus, and sleep apnea [72] . A neuroendocrine basis for the benefits of this procedure has recently been suggested [50] . This procedure is not currently considered first-line treatment, has not been studied in a systematic fashion for IIH, and should be offered only to selected patients on a case-by-case basis. Newer laparoscopic techniques may lower its overall risk, making it a more attractive option in selected IIH patients.
Venous sinus stenting
Neuroimaging shows narrowing of transverse venous sinuses in a large number of IIH patients [40, 44] (Fig. 1c) . There is a persistent debate as to whether these venous abnormalities are cause or consequence of increased ICP. In the former situation, fixed stenoses (e.g. postthrombotic fibrotic changes) could obstruct the venous outflow, increase intracranial venous pressure proximal to the stenosis, and lead to increased ICP as a result of a reduction in CSF absorption via the arachnoid granulations. In this setting, a pressure gradient across the stenosis could be measured and reconstruction of the venous lumen with endovascular stents would be effective in lowering elevated ICP. This procedure has been successfully used [73 ,74] , but seems not to be efficient in all patients [75] . In this model of fixed stenoses, therapeutic reduction of ICP should not affect sinus diameter.
In the latter model (venous abnormalities as a consequence of ICP), elevated ICP could lead to a secondary narrowing of the sinus lumen by compression. It has been suggested that stent angioplasty of the sinuses should not be considered a therapeutic approach in these cases [76 ] . The stenoses in this setting can be reversed by lumbar puncture or shunt surgery [44, 77] . Given the paucity of information regarding visual outcomes from venous sinus stenting and the risk of comorbidities, larger clinical studies must demonstrate long-term safety and efficacy of this procedure before it is adopted for IIH cases refractory to standard treatment [78, 79 ].
Fulminant idiopathic intracranial hypertension
In some patients, IIH presents with severe, rapidly progressive early visual loss. Such patients generally have marked visual field loss or decreased central vision at presentation, with severe papilledema, optic nerve ischemia, and macular edema. Urgent surgery may be required, and temporizing measures such as repeat lumbar punctures, lumbar drainage, and intravenous steroids (for rapid reduction in ICP) should be considered [80 ] .
Conclusion
With the current obesity epidemic, the incidence of IIH in the USA has increased and will almost certainly continue to rise. Unfortunately, despite the implicated mechanisms, complete understanding of IIH remains elusive. Although many patients do well with conservative management, the risk of visual decline is significant with some patients having a chronic disabling course and recurrences. Studies have implicated a role of venous sinus disease in the origin of IIH, with advocates for and against endovascular stent placement, but this modality still remains experimental. Further studies to completely understand the pathophysiology and controlled clinical trials are needed so that our understanding of IIH and its treatment can be optimized. 
